BGX Sofix Ucits Etf

    RNS Number : 3186E
  Bioganix PLC
  25 September 2008
   

    Bioganix Plc ("Bioganix" or "the Group")

    Statement re Possible Offer

    The Company announces that it has received an approach from a third party which, if discussions are successful, might lead to an offer
being made for the entire issued share capital of the Company. It is emphasised that discussions are at an early stage.

    Contacts:

 Nick Helme                                      01568 619 115
 Managing Director - Bioganix Plc

 Julian Morgan                                   01568 619 101
 Finance and Commercial Director - Bioganix Plc

 Mike Coe                                        0117 933 0020
 Blue Oar Securities Plc

 Tom Cooper / Paul Vann                          020 7256 9445
 Winningtons Financial                           0797 122 1972

    Additional Information

    The Directors of Bioganix accept responsibility for the information contained in this announcement. To the best of the knowledge and
belief of the Directors of Bioganix who have taken all reasonable care to ensure that this is the case, such information is in accordance
with the facts and does not omit anything likely to affect the import of such information. This announcement does not constitute an offer or
invitation to purchase or subscribe for any securities.

    Dealing Disclosure Requirements

    Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the "Code"), if any person is, or becomes, "interested"
(directly or indirectly) in 1 per cent. or more of any class of "relevant securities" of Bioganix, all "dealings" in any "relevant
securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities")
must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction.


    This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is
otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of Bioganix, they will be deemed to be a single
person for the purpose of Rule 8.3.

    Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of Bioganix by Bioganix and by any of its
respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the
relevant transaction. A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed, and
the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

    "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in
the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of
securities, or by virtue of any option in respect of, or long derivative referenced to, securities. Terms in quotation marks are defined in
the Code, which can also be found on the Panel's website.

    If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.
     
Rule 2.10 Requirement

    In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, Bioganix confirms that it currently has in issue 8,117,666
ordinary shares of 10p each. 
    
The International Securities Identification Number for the ordinary shares is GB00B128L167.



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
OFDEAANSALAPEFE

Sofix Ucits Etf (LSE:BGX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Sofix Ucits Etf (LSE:BGX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024